Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species

We herein report that experimental murine amyloid A (AA) deposition is accelerated by oral administration of semipurified amyloid fibrils extracted from different species. Three groups of mice were treated with semipurified murine AA amyloid fibrils, semipurified bovine AA amyloid fibrils or semipurified human light chain‐derived (Aλ) amyloid fibrils for 10 days. After 3 weeks, each mouse was subjected to inflammatory stimulation by subcutaneous injection with a mixture of complete Freund’s adjuvant supplemented with Mycobacterium butyricum. The mice were killed on the third day after the inflammatory stimulation, and the spleen, liver, kidney and gastrointestinal tract were examined for amyloid deposits. Amyloid deposits were detected in 14 out of 15 mice treated with murine AA amyloid fibrils, 12 out of 15 mice treated with bovine AA amyloid fibrils and 11 out of 15 mice treated with human Aλ amyloid fibrils. No amyloid deposits were detected in control mice receiving the inflammatory stimulant alone or in amyloid fibril‐treated mice without inflammatory stimulation. Our results suggest that AA amyloid deposition is accelerated by oral administration of semipurified amyloid fibrils when there is a concurrent inflammatory stimulation.

[1]  T. Chiba,et al.  Transmission of Mouse Senile Amyloidosis , 2001, Laboratory Investigation.

[2]  M. Skinner,et al.  Murine amyloid protein AA in casein-induced experimental amyloidosis. , 1977, Laboratory investigation; a journal of technical methods and pathology.

[3]  星井 嘉信 Immunohistochemical classification of 140 autopsy cases with systemic amyloidosis , 1994 .

[4]  T. Niewold,et al.  Fibril Amyloid Enhancing Factor (FAEF)‐Accelerated Amyloidosis in the Hamster is Not Dependent on Serine Esterase Activity and Mononuclear Phagocytosis , 1991, Scandinavian journal of immunology.

[5]  R. Kisilevsky,et al.  Sulfated glycosaminoglycans: a common constituent of all amyloids? , 1987, Laboratory investigation; a journal of technical methods and pathology.

[6]  M. Obana,et al.  Cause of death in 81 autopsied patients with rheumatoid arthritis. , 1994, The Journal of rheumatology.

[7]  G. Glenner,et al.  The 1990 Guidelines for Nomenclature and Classification of Amyloid and Amyloidosis , 1991 .

[8]  A. Cohen,et al.  SECONDARY AMYLOIDOSIS IN LEPROMATOUS LEPROSY. POSSIBLE RELATIONSHIPS OF DIET AND ENVIRONMENT. , 1965, Annals of internal medicine.

[9]  P. Fraser,et al.  New clothes for amyloid enhancing factor (AEF): silk as AEF. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  J. Buxbaum,et al.  The systemic amyloidoses. , 1998, The New England journal of medicine.

[11]  P. Westermark,et al.  Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. , 1994, Biochemical and biophysical research communications.

[12]  T. Blundell,et al.  Structure of pentameric human serum amyloid P component , 1994, Nature.

[13]  Mutsuo Takahashi,et al.  Amyloid enhancing factor (AEF) in the aging mouse , 2004, Virchows Archiv A.

[14]  W. Zschiesche,et al.  Pathology of animal amyloidoses. , 1989, Pharmacology & therapeutics.

[15]  M. Pras,et al.  The characterization of soluble amyloid prepared in water. , 1968, The Journal of clinical investigation.

[16]  E. Cathcart,et al.  Amyloid enhancing factor and dietary transmission in accelerated amyloid A amyloidosis. , 1998, Clinical immunology and immunopathology.

[17]  G. Glenner,et al.  Amyloid. 3. A method for rapid induction of amyloidosis in mice. , 1968, International archives of allergy and applied immunology.

[18]  P. Westermark,et al.  Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[20]  J. Sipe,et al.  Biochemical evidence for the biphasic development of experimental amyloidosis. , 1978, Laboratory investigation; a journal of technical methods and pathology.

[21]  T. Ishihara,et al.  An immunohistochemical study of amyloid P component, apolipoprotein E and ubiquitin in human and murine amyloidoses , 1998, Pathology international.

[22]  S. Cousens,et al.  Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.

[23]  Andrew F. Hill,et al.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD , 1996, Nature.

[24]  Y. Kim,et al.  A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. , 1988, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  M. Skinner,et al.  Further characterization of amyloid-enhancing factor. , 1982, Laboratory investigation; a journal of technical methods and pathology.